By utilizing cohort serum samples from RT-PCR-confirmed COVID-19 patients and healthy controls, we characterized the performance of commercially available LFIA assays obtained from seven different commercial manufacturers for the detection of SARS-CoV-2-specific IgM and IgG antibodies. The gene discussed is CD40LG; the disease is COVID-19.